| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.205.965 |
| Chemical and physical data | |
| Formula | C25H21F4N3O3 |
| Molar mass | 487.455 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AZD-5423 is anonsteroidalglucocorticoid andphase IIexperimental drug being developed byAstraZeneca[1] and disclosed at the spring 2013American Chemical Society meeting in New Orleans to treat respiratory diseases and in particularchronic obstructive pulmonary disease.[2][3][4][5][6]
It has completed a phase II clinical trial.[7]
Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |